Related Experiment Video
Updated: Aug 14, 2026
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Transcriptome sequencing and validation of potential biomarkers associated with cognitive impairment after
Yao Tang1, Boyin Yang1, Xingmei Luo2
1Department of General Ward, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Insights
Researchers identified CXCL8 and FCGR3B as key biomarkers for cognitive impairment following hypertensive cerebral hemorrhage (HCH). These findings offer new insights for managing HCH with cognitive impairment (HCHwCI) and developing targeted therapies.
Area of Science:
- Neuroscience
- Genomics
- Biomarker Discovery
Background:
- Hypertensive cerebral hemorrhage (HCH) is a leading cause of spontaneous intracerebral hemorrhage (ICH).
- Cognitive impairment (CI) is a significant long-term disability after ICH, with poorly understood molecular mechanisms.
- Identifying reliable biomarkers for CI in HCH is crucial for patient management.
Purpose of the Study:
- To identify and validate biomarkers for cognitive impairment (CI) in patients with hypertensive cerebral hemorrhage (HCH).
- To elucidate the molecular mechanisms and regulatory networks associated with CI in HCH.
- To explore potential therapeutic targets for HCH with cognitive impairment (HCHwCI).
Main Methods:
- Transcriptome sequencing of clinical samples to identify differentially expressed genes.
- Protein-protein interaction (PPI) network construction and expression level evaluation.
- Gene set enrichment analysis (GSEA), miRNA/TF regulatory network analysis, drug prediction, and molecular docking.
- Validation of biomarker expression using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Main Results:
- CXCL8 and FCGR3B were identified as significantly upregulated biomarkers in HCH patients with CI, validated by RT-qPCR.
- These biomarkers are enriched in oxidative phosphorylation and related pathways.
- Regulatory networks involving 67 miRNAs and 29 transcription factors (TFs) were predicted for CXCL8 and FCGR3B.
- Computational docking suggested potential therapeutic drugs, including clozapine and a compound identified as 6401-97-4, with good binding activity.
Conclusions:
- CXCL8 and FCGR3B are promising biomarkers for cognitive impairment in hypertensive cerebral hemorrhage (HCH).
- These findings provide a foundation for understanding the molecular basis of HCH with cognitive impairment (HCHwCI).
- The identified biomarkers and regulatory networks offer potential avenues for future therapeutic strategies.
Background:
Hypertensive cerebral hemorrhage (HCH) accounts for the majority of spontaneous intracerebral hemorrhage (ICH) cases. Cognitive impairment (CI) is a major contributor to long-term disability following ICH, yet the molecular mechanisms underlying CI in hypertensive ICH remain poorly understood. Therefore, identifying biomarkers capable of effectively diagnosing or predicting CI in HCH is particularly critical for managing patients with hypertensive cerebral hemorrhage with cognitive impairment (HCHwCI).
Methods:
In this research, clinical samples underwent transcriptome sequencing analysis. Identification of biomarkers associated with CI in HCH was achieved through differential expression analysis, protein-protein interaction (PPI) network construction, and expression level evaluation. Subsequently, to investigate the molecular mechanisms of the biomarkers in HCHwCI, comprehensive analyses were performed, including gene set enrichment analysis (GSEA), molecular regulatory network construction, drug prediction, and molecular docking. Finally, the expression of biomarkers was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Results:
Using 247 differentially expressed CI-related genes (CRGs), we identified CXCL8 and FCGR3B as significantly upregulated biomarkers in HCH patients with CI, a finding subsequently validated by RT-qPCR. CXCL8 and FCGR3B were also found to be significantly enriched in oxidative phosphorylation and other related pathways. The molecular regulation study found that 67 microRNAs (miRNAs) were predicted to regulate CXCL8, and 58 miRNAs were predicted to regulate FCGR3B. Among them, hsa-miR-3168 and hsa-miR-567 jointly regulated both CXCL8 and FCGR3B. In addition, there were 29 transcription factors (TFs) were predicted to target CXCL8, and there were 2 TFs were predicted to target FCGR3B, such as the pairs of CXCL8-STAT6 and FCGR3B-YY1. Moreover, through drug prediction, there were 542 drugs targeting CXCL8 and FCGR3B (such as methotrexate and hydrogen peroxide). Among them, the | Total Score | of FCGR3B and clozapine is 6.3 kcal/mol, and the | Total Score | of CXCL8 and 6401-97-4 is 5.1 kcal/mol, both indicating good binding activity in silico, serving as a proof-of-concept for the computational docking approach.
Conclusion:
In this study, two potential biomarkers, CXCL8 and FCGR3B, were preliminarily identified through transcriptome sequencing combined with biological validation methods to provide novel insights into future therapeutic strategies and research directions for HCHwCI.